About the Company
refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SAVA News
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava Sciences
If you suffered losses exceeding $100,000 investing in Cassava stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner ...
Cassava Sciences: New Year, Same Game Of Smoke And Mirrors
Cassava Sciences reported 2023 cash of $121.1m, $(97.2m) of net loss and R&D expenses increased to $89.4m. Read more on SAVA ...
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
The DSMB is composed of independent clinical research experts who periodically review interim patient safety data for Cassava Sciences’ on-going Phase 3 trials of simufilam in Alzheimer’s disease.
Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go?
Cassava Sciences presented different charts at the CTAD and Lisbon conferences, causing speculation about the reasons for the ...
Cassava Sciences again under scrutiny over Alzheimer's drug research
A lab run a City University of New York (CUNY) scientist with ties to Cassava Sciences (NASDAQ:SAVA) and its Alzheimer's ...
(SAVA) - Analyzing Cassava Sciences's Short Interest
Cassava Sciences's SAVA short percent of float has fallen 3.46% since its last report. The company recently reported that it ...
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
The credibility of the clinical trial results for an experimental Alzheimer's drug has been called into question following a ...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline...
Class Action, Consumer Services, GlobeNewswire, Law & Legal Issues | NEW YORK, (GLOBE NEWSWIRE) -- WHY: Rosen Law ...
SAVA Mar 2024 17.000 put
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a ...
SAVA Apr 2024 20.000 call
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a ...
Cassava: How Nutrition Professionals Assess Its Health Benefits, Nutrition Facts, And More
CherubinBachelor in Nutrition · 5 years of experience · ArgentinaBenefits Cassava helps digestion. It is very easy to digest ...
SAVA Apr 2024 20.500 put
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced plans to present a ...
Loading the latest forecasts...